The agreement provides BCAL with rights to distribute and commercialise the tests in Australia and New Zealand and covers all future tests based on ClearNote Health’s proprietary epigenomics testing platform. BCAL will leverage its existing partnership networks for distribution. BCAL’s growing portfolio of oncology offerings creates new opportunities to work with more doctors and build new strategic partnerships.

BCAL will integrate these new blood tests into its existing and expanding distribution network, which includes a global leader in pathology and diagnostic services, Cancer Care and Associates, and Sydney Breast Clinic. Commencing in Q1 CY26, the agreement is for an initial period of two years, with an option to extend for a further six years.

Strategically, the agreement expands BCAL’s position as a leader in cancer detection, complementing its breast cancer test program by adding high-value, clinically validated cancer tests to BCAL’s pipeline.

Founded in 2016 in California, ClearNote’s core technology was developed by scientists in the Stephen Quake laboratory at Stanford University. The company’s platform builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample. Its highly sensitive, non-invasive Avantect pancreatic and ovarian diagnostic tests may identify cancers in high-risk patient populations earlier than conventional approaches, when patients could be more likely to benefit from treatment.